These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10596021)

  • 1. DNA vaccination of mice with plasmid expressing human papillomavirus 6 major capsid protein L1 elicits type-specific antibodies neutralizing pseudovirions constructed in vitro.
    Matsumoto K; Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
    J Med Virol; 2000 Feb; 60(2):200-4. PubMed ID: 10596021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies.
    Kawana K; Kawana Y; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
    Vaccine; 2001 Jan; 19(11-12):1496-502. PubMed ID: 11163673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16.
    Kowalczyk DW; Wlazlo AP; Shane S; Ertl HC
    Vaccine; 2001 May; 19(25-26):3583-90. PubMed ID: 11348726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses.
    Rocha-Zavaleta L; Alejandre JE; Garcia-Carranca A
    J Med Virol; 2002 Jan; 66(1):86-95. PubMed ID: 11748663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
    Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
    J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and characterization of a preventive and therapeutic HPV DNA vaccine.
    Kim D; Gambhira R; Karanam B; Monie A; Hung CF; Roden R; Wu TC
    Vaccine; 2008 Jan; 26(3):351-60. PubMed ID: 18096279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization against human papillomavirus infection and associated neoplasia.
    Osen W; Jochmus I; Müller M; Gissmann L
    J Clin Virol; 2000 Oct; 19(1-2):75-8. PubMed ID: 11091150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
    Park JS; Oh YK; Kang MJ; Kim CK
    J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.
    Ohlschläger P; Osen W; Dell K; Faath S; Garcea RL; Jochmus I; Müller M; Pawlita M; Schäfer K; Sehr P; Staib C; Sutter G; Gissmann L
    J Virol; 2003 Apr; 77(8):4635-45. PubMed ID: 12663770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of conformational epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination.
    Hines JF; Ghim SJ; Christensen ND; Kreider JW; Barnes WA; Schlegel R; Jenson AB
    Gynecol Oncol; 1994 Oct; 55(1):13-20. PubMed ID: 7525426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
    Roden RB; Yutzy WH; Fallon R; Inglis S; Lowy DR; Schiller JT
    Virology; 2000 May; 270(2):254-7. PubMed ID: 10792983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody.
    Liu DW; Chang JL; Tsao YP; Huang CW; Kuo SW; Chen SL
    Int J Cancer; 2005 Jan; 113(1):93-100. PubMed ID: 15386434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes.
    Dupuy C; Buzoni-Gatel D; Touzé A; Bout D; Coursaget P
    J Virol; 1999 Nov; 73(11):9063-71. PubMed ID: 10516012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.
    Combelas N; Saussereau E; Fleury MJ; Ribeiro T; Gaitan J; Duarte-Forero DF; Coursaget P; Touzé A
    J Transl Med; 2010 Mar; 8():28. PubMed ID: 20334659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective immunity against Chlamydia trachomatis genital infection induced by a vaccine based on the major outer membrane multi-epitope human papillomavirus major capsid protein L1.
    Xu W; Liu J; Gong W; Chen J; Zhu S; Zhang L
    Vaccine; 2011 Mar; 29(15):2672-8. PubMed ID: 21324344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of human papillomavirus type 16 virus-like particles in transgenic plants.
    Biemelt S; Sonnewald U; Galmbacher P; Willmitzer L; Müller M
    J Virol; 2003 Sep; 77(17):9211-20. PubMed ID: 12915537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.
    Cheung YK; Cheng SC; Sin FW; Xie Y
    Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
    Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
    Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.